A time travel journey through cancer therapies

Ana Santos Cravo, R J Mrsny

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The twentieth century was a landmark period in the history of cancer therapies; a time in which conventional cancer treatments such as surgery resection, radiotherapy and chemotherapy made tremendous advances and gave birth to strategies focused on greater selective targeting. Rational drug design allied to rational drug delivery, being led by novel small molecule anti-cancer compounds and monoclonal antibodies. Such approaches prolonged survival time, often without the horrific side effects of previous therapies, but rarely prevented ultimate disease relapse. Selective targeting of membrane transporters and receptors using prodrugs, polymer-cancer drug conjugates and antibody-toxin combinations has contributed to redefine the roadmap of cancer cell targeting. Current pharmacotherapies are still far from consistently delivering cures or sustained remissions. This chapter describes some of the historical events that brought about current cancer targeting strategies.
Original languageEnglish
Title of host publicationCancer targeted drug delivery
Subtitle of host publicationan elusive dream
EditorsY H Bae, R J Mrsny, K Park
Place of PublicationNew York
PublisherSpringer
Pages3-35
Number of pages33
ISBN (Electronic)9781461478768
ISBN (Print)9781461478751
DOIs
Publication statusPublished - 2013

Fingerprint

Neoplasms
Therapeutics
Immunotoxins
Drug Therapy
Membrane Transport Proteins
Drug Design
Prodrugs
Pharmaceutical Preparations
Polymers
Radiotherapy
History
Monoclonal Antibodies
Parturition
Recurrence

Cite this

Santos Cravo, A., & Mrsny, R. J. (2013). A time travel journey through cancer therapies. In Y. H. Bae, R. J. Mrsny, & K. Park (Eds.), Cancer targeted drug delivery: an elusive dream (pp. 3-35). New York: Springer. https://doi.org/10.1007/978-1-4614-7876-8_1

A time travel journey through cancer therapies. / Santos Cravo, Ana; Mrsny, R J.

Cancer targeted drug delivery: an elusive dream. ed. / Y H Bae; R J Mrsny; K Park. New York : Springer, 2013. p. 3-35.

Research output: Chapter in Book/Report/Conference proceedingChapter

Santos Cravo, A & Mrsny, RJ 2013, A time travel journey through cancer therapies. in YH Bae, RJ Mrsny & K Park (eds), Cancer targeted drug delivery: an elusive dream. Springer, New York, pp. 3-35. https://doi.org/10.1007/978-1-4614-7876-8_1
Santos Cravo A, Mrsny RJ. A time travel journey through cancer therapies. In Bae YH, Mrsny RJ, Park K, editors, Cancer targeted drug delivery: an elusive dream. New York: Springer. 2013. p. 3-35 https://doi.org/10.1007/978-1-4614-7876-8_1
Santos Cravo, Ana ; Mrsny, R J. / A time travel journey through cancer therapies. Cancer targeted drug delivery: an elusive dream. editor / Y H Bae ; R J Mrsny ; K Park. New York : Springer, 2013. pp. 3-35
@inbook{6d82b94b80144f668909f2e8fef4ea4d,
title = "A time travel journey through cancer therapies",
abstract = "The twentieth century was a landmark period in the history of cancer therapies; a time in which conventional cancer treatments such as surgery resection, radiotherapy and chemotherapy made tremendous advances and gave birth to strategies focused on greater selective targeting. Rational drug design allied to rational drug delivery, being led by novel small molecule anti-cancer compounds and monoclonal antibodies. Such approaches prolonged survival time, often without the horrific side effects of previous therapies, but rarely prevented ultimate disease relapse. Selective targeting of membrane transporters and receptors using prodrugs, polymer-cancer drug conjugates and antibody-toxin combinations has contributed to redefine the roadmap of cancer cell targeting. Current pharmacotherapies are still far from consistently delivering cures or sustained remissions. This chapter describes some of the historical events that brought about current cancer targeting strategies.",
author = "{Santos Cravo}, Ana and Mrsny, {R J}",
year = "2013",
doi = "10.1007/978-1-4614-7876-8_1",
language = "English",
isbn = "9781461478751",
pages = "3--35",
editor = "Bae, {Y H} and Mrsny, {R J} and K Park",
booktitle = "Cancer targeted drug delivery",
publisher = "Springer",

}

TY - CHAP

T1 - A time travel journey through cancer therapies

AU - Santos Cravo, Ana

AU - Mrsny, R J

PY - 2013

Y1 - 2013

N2 - The twentieth century was a landmark period in the history of cancer therapies; a time in which conventional cancer treatments such as surgery resection, radiotherapy and chemotherapy made tremendous advances and gave birth to strategies focused on greater selective targeting. Rational drug design allied to rational drug delivery, being led by novel small molecule anti-cancer compounds and monoclonal antibodies. Such approaches prolonged survival time, often without the horrific side effects of previous therapies, but rarely prevented ultimate disease relapse. Selective targeting of membrane transporters and receptors using prodrugs, polymer-cancer drug conjugates and antibody-toxin combinations has contributed to redefine the roadmap of cancer cell targeting. Current pharmacotherapies are still far from consistently delivering cures or sustained remissions. This chapter describes some of the historical events that brought about current cancer targeting strategies.

AB - The twentieth century was a landmark period in the history of cancer therapies; a time in which conventional cancer treatments such as surgery resection, radiotherapy and chemotherapy made tremendous advances and gave birth to strategies focused on greater selective targeting. Rational drug design allied to rational drug delivery, being led by novel small molecule anti-cancer compounds and monoclonal antibodies. Such approaches prolonged survival time, often without the horrific side effects of previous therapies, but rarely prevented ultimate disease relapse. Selective targeting of membrane transporters and receptors using prodrugs, polymer-cancer drug conjugates and antibody-toxin combinations has contributed to redefine the roadmap of cancer cell targeting. Current pharmacotherapies are still far from consistently delivering cures or sustained remissions. This chapter describes some of the historical events that brought about current cancer targeting strategies.

U2 - 10.1007/978-1-4614-7876-8_1

DO - 10.1007/978-1-4614-7876-8_1

M3 - Chapter

SN - 9781461478751

SP - 3

EP - 35

BT - Cancer targeted drug delivery

A2 - Bae, Y H

A2 - Mrsny, R J

A2 - Park, K

PB - Springer

CY - New York

ER -